AMSTERDAM, The Netherlands, April 25 /PRNewswire/ -- Primagen Holding BV, a molecular diagnostics company, announced today that the exclusive, worldwide license for the CD133 diagnostic biomarker has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results